We recently published a list of Paul Singer’s Latest Portfolio: Top 10 Stock Picks. In this article, we are going to take a ...

BioMarin (BMRN) announced positive new data from studies of Voxzogo in children with achondroplasia and in ongoing clinical trials ...

Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) was upgraded by stock analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a note issued to investors on Tuesday. BMRN has ...

In a report released today, Allison Bratzel from Piper Sandler maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), ...

Stock analysts at Zacks Research increased their Q1 2025 earnings per share estimates for BioMarin Pharmaceutical in a ...

Oliver and Amelia Carroll have Batten Disease - an incurable genetic disorder that causes rapid decline in a child's ability to walk, talk and see. | ITV News Granada ...

While the job market is tough for life sciences professionals right now, it won’t always be. Employers must continue striving ...

Ichida is a co-founder of AcuraStem and Modulo Bio, a Scientific Advisory Board (SAB) member at Spinogenix, Synapticure, and Vesalius Therapeutics, and a member of the Research and Early Development ...

BioMarin Pharmaceutical (Nasdaq: BMRN) reported $747.31 million in revenue for the fourth quarter, a 16% year-over-year increase. The San Rafael-based global producer of genetic treatments for ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), a biotechnology company specializing in therapies for rare genetic diseases with a market capitalization of $13.15 billion, has been navigating a ...